Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in CML Patients With Suboptimal Response on Imatinib
NCT02086487Phase 4Terminated
- Sponsor
- King Abdullah International Medical Research Center
- Start
- Mar 2013
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of nilotinib in chronic myeloid leukemia (CML), sponsored by King Abdullah International Medical Research Center. Started Mar 2013; status: terminated.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02086487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02086487.